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Objective
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patient group(s) to be studied for sensitivity to olaparib
in a randomised, controlled phase III trial.
Methods
The TO-PARP trial has a multistage phase II design
consisting of a non-randomised component with
response as the primary endpoint followed by a rando-
mised component with overall survival as the primary
endpoint.
Non-randomised component : This part of the trial
design allows rapid progression to a randomised com-
parison if there is evidence of a high response rate (50%
or more) in unselected patients. If the evidence for a
high response rate in unselected patients is weak, bio-
marker defined groups will be investigated for their sen-
sitivity to olaparib.
The first stage will include 30 CRPC patients. If 15
(50%) or more respond then no more patients will be
entered and the randomised component will be under-
taken in unselected patients. Should 2 (7%) or fewer
respond then olaparib will be rejected. If between 3-14
(10%-47%) patients respond then a further 15 patients
will be entered. Should 23 (51%) or more respond
overall then the randomised component will be under-
taken in unselected patients and if 5 (11%) or fewer
respond then olaparib will be rejected. Otherwise with
6-22 responders (13%-49%), biomarker analysis of tis-
sue collected from all 45 patients will be undertaken.
This will aim to identify a sensitive subgroup, with a
response rate which is compatible with a 50% response
rate, warranting further assessment in the randomised
component. If such a subgroup is found, a confirma-
tory single stage 44 patient trial will be undertaken in
this subgroup; this will also serve to pilot prospective
biomarker testing in a multi-centre clinical trial
setting.
Randomised component : This is a phase II controlled,
definitive endpoint assessment of the results generated
in the non-randomised part, offering a more secure
foundation for efficacy before proceeding to phase III.
180 patients will be randomised 2:1 to olaparib or an
appropriate standard of care (a 1-sided 10%, power
80%).
Conclusions
Randomised phase II trials are the gold standard to
establish a basis for treatment efficacy but only a subset
of patients may be sensitive to a new therapy. This pos-
sibility was incorporated into the design of the TO-
PARP trial by introducing a non-randomised initial
component with the potential to identify a sensitive
subgroup.
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